Isradipine is a new dihvdropvridine calcium antagonist shown to he efficacious, safe, and
well tolerated in the treatment of hypertension, regardless of patient age or race. There has …

Isradipine is a calcium channel‐blocking agent of the dihydropyridine type, used in the
treatment of hypertension. A terminal half‐life of 8–9 hr has been reported, in several …

The clinical safety of lacidipine, a new dihydropyridine calcium antagonist, has been
assessed in a longterm, comparative study in hypertensive patients. Slowrelease (SR) …

Seventeen middle-aged males with sustained essential hypertension (WHO stage II) and
diastolic blood pressures (BP) exceeding 100 mm Hg during a placebo run-in period …

This study was undertaken to compare the antihypertensive effect of diltiazem administered
once or twice daily. After a two week wash-out period, eight hypertensive patients were …

The hemodynamic response achieved by isradipine is balanced; there is a marked
decrease in total peripheral resistance with no clinically significant tachycardia or …

An open‐label drug substitution study showed that controlled‐release isradipine (Dynacirc‐
CR) can be safely substituted for amlodipine on a mg‐for‐mg basis in patients with mild‐to …

Ninety-five patients with mild to moderate essential hypertension were randomly treated for
10 weeks with increasing doses of isradipine twice daily (average dose, 13.7±0.8 mg per …

After a placebo run-in phase of four weeks' duration, 1.25 mg or 2.5 mg isradipine twice daily
orally was administered for one year to 23 patients who had been diagnosed as …

This multicenter trial compared the efficacy and safety of isradipine and enalapril in 160
patients with essential hypertension. Patients received isradipine or enalapril for 10 weeks …